GlassScriptPhysician profile
Tatum Reuss
NPI 1740879972
$6,262.74
in general payments reported to CMS, 2019-2025
34 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,561 · 2022: $1,423 · 2023: $932 · 2024: $107 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,166.61 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $998.63 | 2021-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $653.27 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $510.77 | 2021-2023 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $472.69 | 2021-2022 | |
| Lundbeck LLC | $434.13 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $323.29 | 2021-2022 | |
| Neuronetics, INC. | $232.30 | 2021 | |
| Sumitomo Pharma America, INC. | $189.80 | 2023-2025 | Orgovyx, Gemtesa |
| Noven Therapeutics, LLC | $181.53 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $161.09 | 2024-2025 | Provenge |
| Neurocrine Biosciences, INC. | $138.01 | 2021 | |
| Alkermes, INC. | $123.50 | 2022-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $110.12 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $76.93 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $68.60 | 2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $41.66 | 2021 | |
| Idorsia Pharmaceuticals US INC | $37.46 | 2023 | Quviviq |
| Indivior INC. | $35.51 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $32.34 | 2022-2023 | Jornay Pm |
| Eisai INC. | $32.12 | 2021 | |
| Astellas Pharma US INC | $29.16 | 2025 | Xtandi |
| 180 Medical, INC. | $26.91 | 2024 | |
| Orexo US, INC. | $22.81 | 2021 | |
| Adlon Therapeutics L.P. | $19.99 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.65 | 2021 | |
| Pfizer INC. | $19.50 | 2025 | |
| Bausch Health US, LLC | $18.49 | 2021 | |
| Procept Biorobotics Corporation | $16.92 | 2024 | Aquabeam System |
| Alfasigma USA, INC. | $16.50 | 2021 | |
| Boston Scientific Corporation | $14.23 | 2025 | Ams 800 Artificial Urinary Sphincter |
| Almatica Pharma LLC | $13.53 | 2021 | |
| Uswm, LLC | $12.87 | 2021 | |
| Merck Sharp & Dohme LLC | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatum Reuss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.